Lucentis ranibizumab: Phase IIIb data

One-year data from the open-label, U.S. Phase IIIb HORIZON safety extension study of 853 patients with wet AMD from 3 two-year trials, showed that Lucentis ranibizumab given intravitreally on an as-ne...